title: [Monoclonal gammopathy and primary colonic mantle cell lymphoma].
abstract: The association of a monoclonal gammopathy (MG) with a B cell non-Hodgkin's lymphoma (NHL) is a well-known phenomenon. It has been recognized in many subtypes of primary gastrointestinal lymphoma but its association with primary colonic mantle cell lymphoma has never been yet described. We report a 65-year-old man who presented with an exudative ascites and constipation. Serum electrophoresis showed a monoclonal peak in the gamma region of 45g/L and immunoelectrophoresis confirmed the presence of monoclonal gammopathy of IgM kappa type. Bone marrow aspirate was normal. Radiologic and endoscopic investigations evidenced a primary colonic mantle cell lymphoma. Although the association of an MG with an NHL and, in particular, to a primitive digestive location appears a rare phenomenon, endoscopic investigations in patients with MG appears legitimate in the presence of any digestive sign.
authors.affiliation: Service de gastroentérologie, EPS Habib-Thameur, 1008 Tunis, Tunisie. Med.ghanem@yahoo.fr
authors.forename: G
authors.initials: G
authors.lastname: Mohamed
authors.forename: A
authors.initials: A
authors.lastname: Kochlef
authors.forename: D
authors.initials: D
authors.lastname: Gargouri
authors.forename: A
authors.initials: A
authors.lastname: Kilani
authors.forename: H
authors.initials: H
authors.lastname: Elloumi
authors.forename: A
authors.initials: A
authors.lastname: Ouakaa
authors.forename: N
authors.initials: N
authors.lastname: Belhadj
authors.forename: M
authors.initials: M
authors.lastname: Romani
authors.forename: J
authors.initials: J
authors.lastname: Kharrat
authors.forename: A
authors.initials: A
authors.lastname: Ghorbel
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003106:Colon / Q000473:pathology; D003110:Colonic Neoplasms / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007122:Immunoelectrophoresis; D020522:Lymphoma, Mantle-Cell / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D010265:Paraproteinemias / Q000150:complications* / Q000175:diagnosis; D011241:Prednisone / Q000627:therapeutic use; D011860:Radiography, Abdominal; D000069283:Rituximab; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone